https://doi.org/10.55788/36cb592a
Dr Linnea Hedman (Umeå University, Sweden) discussed the new tobacco and nicotine products that have become widely available over recent years. She pointed out that the e-liquid used in e-cigarettes consists of various components such as propylene glycol, glycerine, nicotine, flavour components, and other additives, such as preservatives. The aerosol content may include formaldehyde, acetaldehyde, acrolein, diacetyl, and various metals, all of which impose detrimental (often carcinogenic) health effects in users [1–5]. “The use of e-cigarettes has a generally low prevalence in Sweden,” Dr Hedman said. “It is most common in individuals aged 16 to 44 years [6]. These products are also openly aimed at children and young individuals as they come in colourful containers and attractive flavours such as fruit, mint, and candy.” Although the use of e-cigarettes is often presented as a method to support smoking cessation of ‘ordinary’ tobacco products and may be perceived as less harmful, recent meta-analyses show an association between e-cigarette use and asthma and COPD diagnosis: for asthma, the pooled adjusted odds ratio was 1.39 (95% CI 1.28–1.51) and for COPD 1.49 (95% CI 1.36–1.65) [7,8].
- Goniewicz ML, et al. Tob Control. 2014 Mar;23(2):133-139.
- Williams M, et al. PLoS One. 2013;8(3):e57987.
- Pankow JF, et al. PLoS One. 2017 Mar 8;12(3):e0173055.
- Eshragain E, et al. Tob Prev Cessation. 2021;7(February):10.
- Taylor A, et al. Drug Test Anal. 2021 Feb;13(2):242-260.
- Public Health Agency Sweden.
- Wills TA, et al. Eur Resp J. 2021;57:1901815.
- Hedman L. Who are the e-cigarette users and what are the pulmonary effects of e-cigarette vaping? Nordic Lung Congress 2022, 01–03 June, Copenhagen, Denmark.
Copyright ©2022 Medicom Medical Publishers
Posted on
Previous Article
« Effects of passive vaping in COPD patients Next Article
Points of interest for radiologists screening for lung cancer »
« Effects of passive vaping in COPD patients Next Article
Points of interest for radiologists screening for lung cancer »
Table of Contents: NLC 2022
Featured articles
Respiratory Disease and Physical Activity
Physical activity improves asthma control
Exercise training for IPF patients is feasible but access needs to be improved
Respiratory Disease and Reproduction
PRO-ART study: unravelling the link between asthma and subfertility
Early-onset and uncontrolled asthma: strong association with recurrent pregnancy loss
Palliative Care in Respiratory Diseases
Advance care planning
Biologics in Asthma
Treatable Traits in Obstructive Airway Diseases
Targeting treatable traits allows a personalised approach to management of (severe) asthma
Bronchiectasis
Challenges in Upper Airway Diseases
Exercise-induced laryngeal obstruction (EILO) is often misdiagnosed
The ULANC Group: working together in CRSwNP/asthma
Interstitial Lung Diseases (ILD)
Rheumatoid arthritis-associated ILD
Thoracic ultrasound: a new diagnostic imaging tool in RA-ILD?
Update on treatment of fibrotic ILD
Respiratory Failure
Lung Cancer Screening in the Nordics
Points of interest for radiologists screening for lung cancer
E-cigarettes
E-cigarettes impose detrimental effects on health
Effects of passive vaping in COPD patients
Vaping amongst adolescents: an alarming trend
Tuberculosis and Sarcoidosis
Detection of latent TB infection key to preventing the spread of the disease
Related Articles
August 17, 2022
New antigens in sarcoidosis
August 17, 2022
Sarcoidosis guidelines update
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy
HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com